medigraphic.com
ISSN 1027-2852 (Digital)
ISSN 0864-4551 (Impreso)

2019, Número 3

<< Anterior

Biotecnol Apl 2019; 36 (3)


Comparación de los sistemas comerciales NucliSens® EasyQ® HIV-1 v2.0 y COBAS AmpliPrep/COBAS® TaqMan® 48 HIV-1 v2.0 para la determinación de la carga viral de diferentes variantes genéticas del VIH-1 en pacientes cubanos

Pérez L, Vélez S, Díaz HM, Pintos Y, Machado LY, Kourí V, Blanco-de Armas M

Idioma: Ingles.
Referencias bibliográficas: 41
Paginas: 3221-3226
Archivo PDF: 306.26 Kb.


RESUMEN

La cuantificación de la carga viral del virus de inmunodeficiencia humana tipo 1 en plasma se ha convertido en una herramienta esencial en el seguimiento de los pacientes infectados. El objetivo de este estudio fue comparar los ensayos de carga viral, NucliSENS® EasyQ® HIV-1 v2.0 y COBAS® AmpliPrep/COBAS® TaqMan® 48 HIV-1, en las diferentes formas genéticas virales que circulan en Cuba. Se estudiaron 109 plasmas de pacientes infectados que asistieron a la consulta del Hospital Hermanos Ameijeiras (septiembre/2015 a abril/2016). La carga viral se cuantificó por ambos métodos, los virus se subtiparon mediante secuencia. Las medianas de las cargas virales de 54 muestras mostraron diferencias entre los métodos (p < 0.0001). El 52 % de las muestras presentó diferencias en la cuantificación de la carga viral > 0.5 log UI/mL. El coeficiente de Lin y el método de Bland Altman mostraron una pobre concordancia. Los valores de carga viral para los recombinantes BGs fueron diferentes entre los métodos (p < 0.0091) y fueron menores con el sistema EasyQ®. El método EasyQ® sub-cuantifica los recombinantes CRF_BGs cubanos, lo que limita el empleo de este ensayo para el seguimiento clínico de los pacientes infectados con esta variante viral. Por lo tanto consideramos que no deben emplearse indistintamente los ensayos de carga viral estudiados.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbid Mortal Week Rep. 1992;41:1-19.

  2. Korenromp EL, Williams BG, Schmid GP, Dye C. Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection--a quantitative review. PloS One. 2009;4(6):e5950.

  3. Gupta A, Chaudhary VK, Bhat R. Directed evolution of an anti-human red blood cell antibody. mAbs. 2009;1(3):268-80.

  4. Mellors JW, Margolick JB, Phair JP, Rinaldo CR, Detels R, Jacobson LP, et al. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection. J Am Med Assoc. 2007;297(21):2349-50.

  5. Erikstrup C, Kallestrup P, Zinyama R, Gomo E, Mudenge B, Gerstoft J, et al. Predictors of mortality in a cohort of HIV- 1-infected adults in rural Africa. J Acquir Immun Deficienc Syndr. 2007;44(4): 478-83.

  6. Zhang M, Versalovic J. HIV update. Diagnostic tests and markers of disease progression and response to therapy. Am J Clin Pathol. 2002;118 Suppl:S26-32.

  7. Baldanti F, Paolucci S, Gulminetti R, Brandolini M, Barbarini G, Maserati R. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens. J Med Virol. 2010;82(1):116-22.

  8. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47(2):266-85.

  9. Garcia-Diaz A, Clewley GS, Booth CL, Labett W, McAllister N, Geretti AM. Comparative evaluation of the performance of the Abbott real-time human immunodeficiency virus type 1 (HIV-1) assay for measurement of HIV-1 plasma viral load following automated specimen preparation. J Clin Microbiol. 2006;44(5):1788-91.

  10. Michael NL, Herman SA, Kwok S, Dreyer K, Wang J, Christopherson C, et al. Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved Amplicor HIV-1 Monitor test with isolates of diverse subtypes. J Clin Microbiol. 1999;37(8):2557-63.

  11. Kim JE, Beckthold B, Chen Z, Mihowich J, Malloch L, Gill MJ. Identification of a novel HIV type 1 subtype H/J recombinant in Canada with discordant HIV viral load (RNA) values in three different commercial assays. AIDS Res Hum Retrovir. 2007;23(11):1309-13.

  12. Cuevas MT, Ruibal I, Villahermosa ML, Diaz H, Delgado E, Parga EV, et al. High HIV-1 genetic diversity in Cuba. AIDS (London). 2002;16(12):1643-53.

  13. Perez L, Thomson MM, Bleda MJ, Aragones C, Gonzalez Z, Perez J, et al. HIV type 1 molecular epidemiology in Cuba: high genetic diversity, frequent mosaicism, and recent expansion of BG intersubtype recombinant forms. AIDS Res Hum Retrovir. 2006;22(8):724-33.

  14. Thomson MM, Casado G, Posada D, Sierra M, Najera R. Identification of a novel HIV-1 complex circulating recombinant form (CRF18_cpx) of Central African origin in Cuba. AIDS (London). 2005;19(11):1155-63.

  15. Casado G, Thomson MM, Sierra M, Najera R. Identification of a novel HIV-1 circulating ADG intersubtype recombinant form (CRF19_cpx) in Cuba. J Acquir Immun Deficienc Syndr. 2005;40(5):532-7.

  16. Aleman Y, Vinken L, Kouri V, Perez L, Alvarez A, Abrahantes Y, et al. Performance of an in-house human immunodeficiency virus type 1 genotyping system for assessment of drug resistance in Cuba. PloS One. 2015;10(2):e0117176.

  17. Paba P, Fabeni L, Ciccozzi M, Perno CF, Ciotti M. Performance evaluation of the COBAS/TaqMan HIV-1 v2.0 in HIV- 1 positive patients with low viral load: a comparative study. J Virol Methods. 2011;173(2):399-402.

  18. Xu S, Song A, Nie J, Li X, Wang Y. Performance of NucliSens HIV-1 EasyQ Version 2.0 compared with six commercially available quantitative nucleic acid assays for detection of HIV-1 in China. Mol Diagn Ther. 2010;14(5):305-16.

  19. Aragones C, Campos J, Perez D, Martinez A, Perez J. SIDATRAT: Informatics to Improve HIV/AIDS Care. MEDICC Rev. 2012;14(4):5-9.

  20. Biomerieux. Información del producto NucliSENS EasyQ® HIV-1 v2.0. Available from: www.who. int/.../120109_0127_016_00_public_report_ v1.pdf.

  21. Roche. Información del producto COBAS AmpliPrep-COBAS TaqMan 48 HIV-1. Available from: https://molecular. roche.com.

  22. Carrasco JL, Jover L. Métodos estadísticos para evaluar la concordancia. Med Clín. 2004;1:28-34.

  23. studies. Mimtaomc. [database on the Internet] 1983 [cited http://smm. sagepub.com/].

  24. Infection CGotUoADfTaPH. Recommendations for a Public Health Approach. Geneva: World

  25. Cuevas M, Fernandez-Garcia A, Sanchez-Garcia A, Gonzalez-Galeano M, Pinilla M, Sanchez-Martinez M, et al. Incidence of non-B subtypes of HIV-1 in Galicia, Spain: high frequency and diversity of HIV-1 among men who have sex with men. Euro Surveil. 2009;14(47):19413.

  26. Holguin A, de Mulder M, Yebra G, Lopez M, Soriano V. Increase of non- B subtypes and recombinants among newly diagnosed HIV-1 native Spaniards and immigrants in Spain. Curr HIV Res. 2008;6(4):327-34.

  27. Kouri V, Aleman Y, Perez L, Perez J, Fonseca C, Correa C, et al. High frequency of antiviral drug resistance and non-B subtypes in HIV-1 patients failing antiviral therapy in Cuba. J Clin Virol. 2012;55(4):348-55.

  28. Machado LY, Blanco M, Dubed M, Diaz HM, Ruiz NM, Valdes N, et al. HIV type 1 genetic diversity in newly diagnosed Cuban patients. AIDS Res Hum Retrovir. 2012;28(8):956-60.

  29. Perez L, Kouri V, Aleman Y, Abrahantes Y, Correa C, Aragones C, et al. Antiretroviral drug resistance in HIV-1 therapynaive patients in Cuba. Infect Genet Evol. 2013;16:144-50.

  30. Grgic I, Zidovec Lepej S, Vince A, Begovac J. Increased frequency of viral loads above 100,000 HIV-1 RNA copies/ml measured by Roche Cobas TaqMan assay in comparison with Cobas Amplicor assay. J Clin Virol. 2010;48(1):75-6.

  31. Munera-Jaramillo MI, Ramirez-Puerta BS, Carrillo-Ávila SM, Rojas-Ríos R. Comparación de los métodos de cuantificación de carga viral de VIH: COBAS® AmpliPrep/ COBAS® TaqMan HIV-1 test, v 2.0, y VERSANT HIV-1 RNA 1.0 Assay. 2012. Infectio. 2012;16(1):8-14.

  32. Sollis KA, Smit PW, Fiscus S, Ford N, Vitoria M, Essajee S, et al. Systematic review of the performance of HIV viral load technologies on plasma samples. PloS One. 2014;9(2):e85869.

  33. de Mendoza C, Koppelman M, Montes B, Ferre V, Soriano V, Cuypers H, et al. Multicenter evaluation of the NucliSens EasyQ HIV-1 v1.1 assay for the quantitative detection of HIV-1 RNA in plasma. J Virol Methods. 2005;127(1):54-9.

  34. Yao J, Liu Z, Ko LS, Pan G, Jiang Y. Quantitative detection of HIV-1 RNA using NucliSens EasyQ HIV-1 assay. J Virol Methods. 2005;129(1):40-6.

  35. Scott LE, Noble LD, Moloi J, Erasmus L, Venter WD, Stevens W. Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays. J Clin Microbiol. 2009;47(7):2209-17.

  36. Troppan KT, Stelzl E, Violan D, Winkler M, Kessler HH. Evaluation of the new VERSANT HIV-1 RNA 1.0 Assay (kPCR) for quantitative detection of human immunodeficiency virus type 1 RNA. J Clin Virol. 2009;46(1):69-74.

  37. Greengrass VL, Plate MM, Steele PM, Denholm JT, Cherry CL, Morris LM, et al. Evaluation of the Cavidi ExaVir Load assay (version 3) for plasma human immunodeficiency virus type 1 load monitoring. J Clin Microbiol. 2009;47(9):3011-3.

  38. Korn K, Weissbrich B, Henke-Gendo C, Heim A, Jauer CM, Taylor N, et al. Single-point mutations causing more than 100-fold underestimation of human immunodeficiency virus type 1 (HIV-1) load with the Cobas TaqMan HIV-1 Real-Time PCR Assay. J Clin Microbiol. 2009;47(4):1238-40.

  39. Church D, Gregson D, Lloyd T, Klein M, Beckthold B, Laupland K, et al. Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections. J Clin Microbiol. 2011;49(1):118-24.

  40. Colson P, Solas C, Moreau J, Motte A, Henry M, Tamalet C. Impaired quantification of plasma HIV-1 RNA with a commercialized real-time PCR assay in a couple of HIV-1-infected individuals. J Clin Virol. 2007;39(3):226-9.

  41. Katsoulidou A, Rokka C, Issaris C, Haida C, Tzannis K, Sypsa V, et al. Comparative evaluation of the performance of the Abbott RealTime HIV-1 assay for measurement of HIV-1 plasma viral load on genetically diverse samples from Greece. Virol J. 2011;8:10.




2020     |     www.medigraphic.com